Research update: 8 October 2026.

Weight-loss medicines regularly make headlines. New research is exploring amylin, a hormone pathway involved in appetite and fullness, both on its own and alongside incretin medicines. For patients in Dubai, these developments are worth understanding—but a trial result does not establish approval, local availability or suitability for an individual.

What is amylin?

Amylin and GLP-1 act through different receptor pathways. Investigational medicines may target amylin alone or combine it with another treatment. These approaches can have different benefits and risks and should not be treated as interchangeable.

CagriSema: exploring appetite and food-related thoughts

CagriSema combines cagrilintide with semaglutide. Novo Nordisk’s September 2026 announcement describes a 52-week functional MRI study examining brain responses to food cues and changes in appetite-related measures. It reports a 22.4% estimated treatment difference in body-weight reduction versus placebo at 52 weeks. That figure belongs to this particular study, rather than to every CagriSema trial.

Separate analyses studied organ fat and bone markers in adults with type 2 diabetes. These remain emerging findings; they do not establish prevention of fractures or a cure for liver disease. Novo described CagriSema as investigational. Its anticipated US regulatory decision does not establish UAE approval or availability.

EloraTZP: benefits and tolerability both matter

Lilly reported a 48-week phase 2b study involving 367 adults with overweight or obesity and type 2 diabetes. Under the trial’s efficacy analysis, the highest tested combination of eloralintide and tirzepatide produced 23.3% average weight loss, compared with 14.8% for tirzepatide 15 mg.

These results represent study averages in a specific population, not expected outcomes for every patient. Gastrointestinal adverse events were more frequent in the combination groups. Discontinuation due to adverse events ranged from 10.8% to 27%, compared with 2.9% with tirzepatide alone. Further phase 3 research was planned. “Newer” therefore does not automatically mean “fewer side effects.”

Petrelintide: studying amylin alone

The published phase 2 ZUPREME-1 study evaluated petrelintide in adults with overweight or obesity without diabetes. Mean weight reduction reached 9.8% in one group at the primary 28-week assessment, compared with 1.7% with placebo. Later results reached up to 10.7% at week 42.

Nausea occurred in 20% of petrelintide participants versus 6% receiving placebo. Some other gastrointestinal outcomes were more similar. These findings support further evaluation; they do not prove superiority to GLP-1 medicines through a direct comparison.

What do these headlines mean for Dubai patients?

Different study populations, doses, durations and analyses prevent reliable ranking of medicines by headline percentages. A consultation should consider medical history, current medicines, goals, side effects and follow-up.

Explore MyCare’s doctor-guided weight-management programme in Dubai. An assessment does not guarantee eligibility for a particular medicine.

Frequently asked questions

Are amylin medicines the same as GLP-1 medicines?

No; they act through different pathways, although some investigational combinations use both.

Do newer medicines always have fewer side effects?

No. Benefits and tolerability must be assessed together.

Are these medicines available in Dubai?

This article does not establish UAE approval or availability. Ask a licensed clinician about current approved options.

Should I change my current treatment?

Discuss any change with your prescribing clinician.

Sources

This research update provides general information and does not replace individual medical advice.

Beyond GLP-1: What New Weight-Loss Research Means for Patients in Dubai